Related Experiment Video

Updated: May 18, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human

Dimitrios Zardavas1, Ivana Bozovic-Spasojevic, Evandro de Azambuja

  • 1Institut Jules Bordet, l'Université Libre de Bruxelles, Brussels, Belgium.

Current Opinion in Oncology
|September 28, 2012
PubMed
Abstract

Insights

Dual HER2 blockade, combining multiple anti-HER2 agents, shows promise in treating HER2-positive breast cancer. This strategy improves response rates in metastatic and neoadjuvant settings, with ongoing research in adjuvant therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Recent development of diverse anti-HER2 targeted agents.
  • Preclinical and clinical validation of dual anti-HER2 blockade strategies.
  • Established efficacy of single-agent anti-HER2 therapy in HER2-positive breast cancer.

Purpose of the Study:

  • Review the biologic rationale for dual HER2 blockade.
  • Summarize clinical findings of dual anti-HER2 blockade therapies.
  • Discuss future directions and challenges in dual anti-HER2 therapy.

Main Methods:

  • Review of preclinical studies on dual HER2 blockade.
  • Analysis of clinical trial data for dual anti-HER2 agents in various settings.
  • Synthesis of current literature on HER2-targeted therapies.

Main Results:

  • Dual anti-HER2 blockade demonstrates significant efficacy in metastatic breast cancer, including chemotherapy-free regimens.
  • Combinations of dual anti-HER2 blockade with chemotherapy nearly double pathologic complete response rates in the neoadjuvant setting.
  • Positive outcomes observed even in heavily pretreated patients, suggesting broad applicability.

Conclusions:

  • Combining anti-HER2 agents is a promising therapeutic strategy now entering clinical practice.
  • Challenges include managing resistance mechanisms and optimizing combination regimens.
  • Future clinical trials are essential to refine strategies and identify patients who may avoid chemotherapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...